Picture of Alpha Cognition logo

ACOG Alpha Cognition Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapMomentum Trap

Momentum

Relative Strength (%)
1m-13.93%
3m-30.08%
6m-39.71%
1yr+6.47%
Volume Change (%)
10d/3m+39.65%
Price vs... (%)
52w High-53.94%
50d MA-15.04%
200d MA-34.02%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-2385.28%
Return on Equityn/a
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Alpha Cognition EPS forecast chart

Profile Summary

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    June 30th, 2024
    Incorporated
    November 15th, 2017
    Public Since
    September 19th, 2018
    No. of Employees
    4
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    ca flag iconCanadian Securities Exchange
    Shares in Issue
    6,034,215

    ACOG Share Price Performance

    Upcoming Events for ACOG

    Similar to ACOG

    Picture of Albert Labs International logo

    Albert Labs International

    ca flag iconCanadian Securities Exchange

    Picture of Algernon Pharmaceuticals logo

    Algernon Pharmaceuticals

    ca flag iconCanadian Securities Exchange

    Picture of Asep Medical Holdings logo

    Asep Medical Holdings

    ca flag iconCanadian Securities Exchange

    Picture of Awakn Life Sciences logo

    Awakn Life Sciences

    ca flag iconCanadian Securities Exchange

    Picture of BetterLife Pharma logo

    BetterLife Pharma

    ca flag iconCanadian Securities Exchange

    FAQ